Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Maastricht University Medical Center
DEKA Biosciences
BioAtla, Inc.
SecuraBio
Jules Bordet Institute
Hunan Cancer Hospital